BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Solara Active Pharma Science Ltd. delivered lower-than-expected operational performance in Q4 FY22. However, it has recouped sales and turned Ebitda positive on a QoQ basis.
We have revised our estimates to factor in:
the cancellation of merger with Aurore Life Sciences Pvt. Ltd., and
gradual normalisation of gross margin as well as operating leverage.
Accordingly, we have cut our estimates by 85%/67% for FY23/FY24.
With Solara Active Pharma's senior management changes over the past three to six months, the course correction is underway. We believe the financial performance to be at trough and improve gradually going forward.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR